Pfizer, Valneva report Lyme vaccine success

Pfizer and Valneva have announced positive topline results from a Phase 3 study of their Lyme disease vaccine candidate. The trial demonstrated strong efficacy, marking a significant milestone in the development of a much-needed preventative measure against Lyme disease. These encouraging findings suggest the vaccine candidate is effective in protecting against the tick-borne illness. The companies are expected to proceed with further regulatory steps based on this successful outcome, potentially bringing a new tool to combat Lyme disease to the market.